Combination therapy for advanced breast cancer after prior treatment failure
Part of Cancer clinical trials.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced hormone-positive, HER2-negative breast cancer that has worsened after CDK4/6 inhibitor treatment. The goal is to see if this combination can slow cancer growth for a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 75.
- Your breast cancer must be hormone receptor-positive (HR+) and HER2-negative (confirming by biopsy).
- You must have already tried a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) and it either stopped working or you couldn't tolerate it.
- You must be postmenopausal (or willing to have ovarian suppression, if premenopausal).
- You should have at least one tumor that can be measured by scans.
- You need to be in generally good health (able to do daily activities, with no severe organ problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.